Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Physicians' recognize benefits of genetic testing; say formal education required to put it into practice

Medco Health Solutions, Inc.(NYSE: MHS) and the American Medical Association (AMA) today announced the findings of a national benchmark survey on physicians' acceptance, use and education regarding pharmacogenomic testing.

23 Oct 2009

Exposing pregnant women to chemotherapy does not affect the foetus

Professor Frederic Amant of the Katholieke Universiteit Leuven (K.U.Leuven) directs research into the treatment of cancer in pregnant women and the consequences of such treatment on foetal development. In her PhD dissertation on chemotherapy during pregnancy, Kristel Van Calsteren presents new scientific discoveries.

23 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Vidacare to release results of validation study on its OnControl Bone Marrow System

Vidacare Corporation has completed an analysis and is releasing the results of a validation study on its OnControl™ Bone Marrow System, the first effort in decades to improve the safety, control, and comfort of bone marrow aspiration and biopsy procedures.

23 Oct 2009

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

The Side-Out Foundation and its Dig Pink- Volleyball Breast Cancer Awareness campaign will launch a first of its kind clinical trial this month to examine the effects of individualized treatment on patients with metastatic breast cancer.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear.

23 Oct 2009

Applied Biosystems announces the global availability of its 3500 Series Genetic Analyzer

Applied Biosystems, part of Life Technologies Corporation, today announced the global commercial availability of a new capillary electrophoresis (CE) sequencing system. The 3500 Series Genetic Analyzer builds on Applied Biosystems’ industry-leading CE sequencing systems, with state-of-the-art advancements, setting significant new standards for throughput, data quality and ease of use.

22 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Halozyme Therapeutics, Inc. today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro. The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations.

22 Oct 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2009.

22 Oct 2009

Medipattern to introduce its B-CAD-FOR-LIFE program at RSNA 2009

The Medipattern Corporation ("Medipattern"), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, will be introducing its B-CAD-FOR-LIFE™ program at RSNA 2009.

22 Oct 2009

Peripheral arterial disease linked to lifestyle changes

Modifying the risk of peripheral arterial disease (or PAD)-with healthy lifestyle changes-remains vital to one's health, note researchers in a recent issue of the Journal of Vascular and Interventional Radiology. And while PAD can progress and worsen over time, there is not enough evidence yet to advocate minimally invasive treatment in patients who have had a narrowing or blockage of a leg artery but showing no signs or symptoms of the disease, say Irish researchers in a retrospective study of more than 900 individuals.

22 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

Sectra signs distribution agreement with Attieh Medico

The Swedish IT and medical-technology company Sectra has signed a distribution agreement with Attieh Medico, a leading medical technology company in the Kingdom of Saudi Arabia.

22 Oct 2009

Complex issue of CER in biopharmaceutical development explored

In a new report released today, John Doyle, Vice President and Practice Leader for Quintiles Consulting, and an expert on pharmaceutical market access, explores the complex issue of comparative effectiveness research (CER) and its strategic importance in successful and efficient biopharmaceutical development.

22 Oct 2009

Cephalon announces receipt of a Paragraph IV Certification Notice Letter regarding ANDA

Cephalon, Inc. (Nasdaq: CEPH) today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by Teva Pharmaceuticals USA, Inc. requesting approval to market and sell a generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths of NUVIGIL® (armodafinil) Tablets [C-IV].

22 Oct 2009

Oncology News and Research

Further Reading

Physicians' recognize benefits of genetic testing; say formal education required to put it into practice

Exposing pregnant women to chemotherapy does not affect the foetus

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Vidacare to release results of validation study on its OnControl Bone Marrow System

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Early diagnostic for ovarian cancer to be developed

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

Applied Biosystems announces the global availability of its 3500 Series Genetic Analyzer

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Celgene announces fiscal 2009 third-quarter results

Faster insulin absorption for varying insulin doses and PH20 concentrations demonstrated

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Medipattern to introduce its B-CAD-FOR-LIFE program at RSNA 2009

Peripheral arterial disease linked to lifestyle changes

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Sectra signs distribution agreement with Attieh Medico

Complex issue of CER in biopharmaceutical development explored

Cephalon announces receipt of a Paragraph IV Certification Notice Letter regarding ANDA

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News